AstraZeneca launches new health technology business
The new business, Evinova, will provide digital health solutions to pharma, biotech, and clinical research organisations (CROs) to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Nov 23
The new business, Evinova, will provide digital health solutions to pharma, biotech, and clinical research organisations (CROs) to…
21 Nov 23
Under the partnership, both the firms will jointly develop and produce NK cells and help in the development…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Nov 23
The collaboration aims to advance the development, production, and commercialisation of HSK31858, a groundbreaking reversible dipeptidyl peptidase 1…
21 Nov 23
Research aims to employ RION's exosome technology platform to better understand regenerative medicine in war zones for pulmonary…
20 Nov 23
AstraZeneca secured the FDA approval based on positive results from Phase 3 CAPItello-291 clinical trial that evaluated the…
17 Nov 23
Casgevy is a genetically modified autologous CD34+ cell-enriched population that contains human hematopoietic stem and progenitor cells, edited…
17 Nov 23
The opening of Lilly's first significant production complex in Germany is aligned with the strategy to produce essential…
17 Nov 23
The indicated use is for the initial treatment of adults diagnosed with locally advanced unresectable or metastatic human…
17 Nov 23
The agreement includes upfront funding, and milestone payments, in addition to royalties on any approved products arising from…
16 Nov 23
Astellas will obtain Propella’s lead candidate PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor intended for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates